前立腺癌診断薬市場規模、シェア、動向分析レポート:検査タイプ別(予備検査、確認検査)、タイプ別(腺癌、間質細胞癌、その他)、エンドユース別、地域別、セグメント別予測、2024年~2030年Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary Tests, Confirmatory Tests), By Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), By End Use, By Region, And Segment Forecasts, 2024 - 2030 前立腺がん診断薬市場の成長と動向 Grand View Research, Inc.の最新レポートによると、前立腺癌診断の世界市場規模は、2024年から2030年にかけてCAGR 6.4%で拡大し、2030年には131億6000万米ドルに達すると... もっと見る
1~3営業日
サマリー前立腺がん診断薬市場の成長と動向Grand View Research, Inc.の最新レポートによると、前立腺癌診断の世界市場規模は、2024年から2030年にかけてCAGR 6.4%で拡大し、2030年には131億6000万米ドルに達すると予測されている。政府の支援策、世界的な疾患有病率の増加、前立腺癌の有病率の上昇と確定診断検査の技術的進歩がこの市場の主な促進要因である。 効果的な診断と治療に焦点を当てた研究を強化するための有利な政府のイニシアチブの増加は、予測期間中の市場成長を促進すると予想される。例えば、国立がん研究所は、「アフリカ系男性の前立腺がんに関する研究」と題する研究を開始した:遺伝学、腫瘍マーカー、社会的ストレスの役割の定義」(RESPOND)である。この研究は、アフリカ系アメリカ人男性の前立腺癌に関連する非生物学的および生物学的因子を研究する最大の共同研究である。この研究は、National Institute on Minority Health and NCI and Health DisparitiesがProstate Cancer Foundationと共同で立ち上げたもので、2,600万米ドルの資金が提供された。 ノーフォーク大学およびイースト・アングリア大学の研究者たちは、ノリッジ大学病院とともに、診断から5年以内に治療処置が必要になる可能性が最大8倍低い男性を特定するのに役立つ非侵襲的尿検査を開発した。このような技術的進歩も、近い将来、市場の可能性に影響を与えると予想される。 さらに、カロリンスカ研究所とKTH研究所の研究者たちは、空間トランスクリプトミクスに人工知能を用いることで、前立腺がんの早期発見に役立ち、それによって臨床診断と治療が改善されると結論づけた。空間トランスクリプトミクスは、通常、活性遺伝子とその組織像の定量分析を組み合わせた手法であり、効果的な疾患診断に役立つ。 前立腺癌診断市場レポートハイライト - 2023年の市場シェアは確認検査が最大。このセグメントは66.4%で最大の市場シェアを占めている。確認検査には、PCA3検査、経直腸超音波検査(TRUS)、患部の生検などが含まれる。 - 最終用途に基づき、市場は病院、外来患者施設、在宅医療、研究・製造に区分される。2023年には、外来患者施設セグメントが市場を支配した。外来施設は、認定医の取得と経験により、より快適なコンサルティングと治療システムを革命的に開発した。 - 北米地域は、有病率の上昇と診断強化のための政府イニシアチブの高まりにより、最大の市場シェアを占めている。 目次Table of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Segment Definitions 1.2.1. Test Type 1.2.2. Type 1.2.3. End Use 1.2.4. Regional scope 1.2.5. Estimates and forecasts timeline 1.3. Research Methodology 1.4. Information Procurement 1.4.1. Purchased database 1.4.2. GVR’s internal database 1.4.3. Secondary sources 1.4.4. Primary research 1.4.5. Details of primary research 1.4.5.1. Data for primary interviews in North America 1.4.5.2. Data for primary interviews in Europe 1.4.5.3. Data for primary interviews in Asia Pacific 1.4.5.4. Data for primary interviews in Latin America 1.4.5.5. Data for Primary interviews in MEA 1.5. Information or Data Analysis 1.5.1. Data analysis models 1.6. Market Formulation & Validation 1.7. Model Details 1.7.1. Commodity flow analysis (Model 1) 1.7.2. Approach 1: Commodity flow approach 1.7.3. Volume price analysis (Model 2) 1.7.4. Approach 2: Volume price analysis 1.8. List of Secondary Sources 1.9. List of Primary Sources 1.10. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Test Type 2.2.2. Type 2.2.3. End Use 2.2.4. Regional outlook 2.3. Competitive Insights Chapter 3. Prostate Cancer Diagnostics Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Market Dynamics 3.2.1. Market driver analysis 3.2.1.1. Increasing prevalence of prostate cancer 3.2.1.2. Increasing global geriatric population 3.2.1.3. Technological advancements in the field of cancer diagnostics 3.2.2. Market restraint analysis 3.2.2.1. High cost of diagnostics 3.3. Prostate Cancer Diagnostics Market Analysis Tools 3.3.1. Industry Analysis - Porter’s 3.3.1.1. Supplier power 3.3.1.2. Buyer power 3.3.1.3. Substitution threat 3.3.1.4. Threat of new entrant 3.3.1.5. Competitive rivalry 3.3.2. PESTEL Analysis 3.3.2.1. Political landscape 3.3.2.2. Technological landscape 3.3.2.3. Economic landscape Chapter 4. Prostate Cancer Diagnostics Market: Test Type Estimates & Trend Analysis 4.1. Test Type Market Share, 2023 & 2030 4.2. Segment Dashboard 4.3. Global Prostate Cancer Diagnostics Market by Test Type Outlook 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 4.4.1. Preliminary Tests 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.1.2. PSA Tests 4.4.1.2.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.1.3. Free PSA Test 4.4.1.3.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.1.4. Total PSA Test 4.4.1.4.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.1.5. Other Preliminary Tests 4.4.1.5.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2. Confirmatory Tests 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2.2. Pca3 Test 4.4.2.2.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2.3. Trans-Rectal Ultrasound 4.4.2.3.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2.4. Biopsy Test 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 5. Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis 5.1. Type Market Share, 2023 & 2030 5.2. Segment Dashboard 5.3. Global Prostate Cancer Diagnostics Market by Type Outlook 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 5.4.1. Adenocarcinoma 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million) 5.4.2. Interstitial Cell Carcinoma 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) 5.4.3. Other 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 6. Prostate Cancer Diagnostics Market: End Use Estimates & Trend Analysis 6.1. End-use Market Share, 2023 & 2030 6.2. Segment Dashboard 6.3. Global Prostate Cancer Diagnostics Market by End Use Outlook 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 6.4.1. Hospitals 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.2. Outpatient Facilities 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.3. Home Care 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.4. Research & Manufacturing 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 7. Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis 7.1. Regional Market Share Analysis, 2023 & 2030 7.2. Regional Market Dashboard 7.3. Global Regional Market Snapshot 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030: 7.5. North America 7.5.1. U.S. 7.5.1.1. Key country dynamics 7.5.1.2. Regulatory framework/ reimbursement structure 7.5.1.3. Competitive scenario 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) 7.5.2. Canada 7.5.2.1. Key country dynamics 7.5.2.2. Regulatory framework/ reimbursement structure 7.5.2.3. Competitive scenario 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) 7.6. Europe 7.6.1. UK 7.6.1.1. Key country dynamics 7.6.1.2. Regulatory framework/ reimbursement structure 7.6.1.3. Competitive scenario 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) 7.6.2. Germany 7.6.2.1. Key country dynamics 7.6.2.2. Regulatory framework/ reimbursement structure 7.6.2.3. Competitive scenario 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) 7.6.3. France 7.6.3.1. Key country dynamics 7.6.3.2. Regulatory framework/ reimbursement structure 7.6.3.3. Competitive scenario 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) 7.6.4. Italy 7.6.4.1. Key country dynamics 7.6.4.2. Regulatory framework/ reimbursement structure 7.6.4.3. Competitive scenario 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) 7.6.5. Spain 7.6.5.1. Key country dynamics 7.6.5.2. Regulatory framework/ reimbursement structure 7.6.5.3. Competitive scenario 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) 7.6.6. Norway 7.6.6.1. Key country dynamics 7.6.6.2. Regulatory framework/ reimbursement structure 7.6.6.3. Competitive scenario 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) 7.6.7. Sweden 7.6.7.1. Key country dynamics 7.6.7.2. Regulatory framework/ reimbursement structure 7.6.7.3. Competitive scenario 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) 7.6.8. Denmark 7.6.8.1. Key country dynamics 7.6.8.2. Regulatory framework/ reimbursement structure 7.6.8.3. Competitive scenario 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) 7.7. Asia Pacific 7.7.1. Japan 7.7.1.1. Key country dynamics 7.7.1.2. Regulatory framework/ reimbursement structure 7.7.1.3. Competitive scenario 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) 7.7.2. China 7.7.2.1. Key country dynamics 7.7.2.2. Regulatory framework/ reimbursement structure 7.7.2.3. Competitive scenario 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) 7.7.3. India 7.7.3.1. Key country dynamics 7.7.3.2. Regulatory framework/ reimbursement structure 7.7.3.3. Competitive scenario 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) 7.7.4. Australia 7.7.4.1. Key country dynamics 7.7.4.2. Regulatory framework/ reimbursement structure 7.7.4.3. Competitive scenario 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) 7.7.5. South Korea 7.7.5.1. Key country dynamics 7.7.5.2. Regulatory framework/ reimbursement structure 7.7.5.3. Competitive scenario 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) 7.7.6. Thailand 7.7.6.1. Key country dynamics 7.7.6.2. Regulatory framework/ reimbursement structure 7.7.6.3. Competitive scenario 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) 7.8. Latin America 7.8.1. Brazil 7.8.1.1. Key country dynamics 7.8.1.2. Regulatory framework/ reimbursement structure 7.8.1.3. Competitive scenario 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) 7.8.2. Mexico 7.8.2.1. Key country dynamics 7.8.2.2. Regulatory framework/ reimbursement structure 7.8.2.3. Competitive scenario 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) 7.8.3. Argentina 7.8.3.1. Key country dynamics 7.8.3.2. Regulatory framework/ reimbursement structure 7.8.3.3. Competitive scenario 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) 7.9. MEA 7.9.1. South Africa 7.9.1.1. Key country dynamics 7.9.1.2. Regulatory framework/ reimbursement structure 7.9.1.3. Competitive scenario 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) 7.9.2. Saudi Arabia 7.9.2.1. Key country dynamics 7.9.2.2. Regulatory framework/ reimbursement structure 7.9.2.3. Competitive scenario 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) 7.9.3. UAE 7.9.3.1. Key country dynamics 7.9.3.2. Regulatory framework/ reimbursement structure 7.9.3.3. Competitive scenario 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) 7.9.4. Kuwait 7.9.4.1. Key country dynamics 7.9.4.2. Regulatory framework/ reimbursement structure 7.9.4.3. Competitive scenario 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Recent Developments & Impact Analysis, By Key Market Participants 8.2. Company/Competition Categorization 8.3. Vendor Landscape 8.3.1. List of key distributors and channel partners 8.3.2. Key customers 8.3.3. Key company market share analysis, 2023 8.3.4. MDx Health 8.3.4.1. Company overview 8.3.4.2. Financial performance 8.3.4.3. Test Type benchmarking 8.3.4.4. Strategic initiatives 8.3.5. Myriad Genetics, Inc. 8.3.5.1. Company overview 8.3.5.2. Financial performance 8.3.5.3. Test Type benchmarking 8.3.5.4. Strategic initiatives 8.3.6. Abbott Laboratories 8.3.6.1. Company overview 8.3.6.2. Financial performance 8.3.6.3. Test Type benchmarking 8.3.6.4. Strategic initiatives 8.3.7. F. Hoffman-La Roche AG 8.3.7.1. Company overview 8.3.7.2. Financial performance 8.3.7.3. Test Type benchmarking 8.3.7.4. Strategic initiatives 8.3.8. Bayer AG 8.3.8.1. Company overview 8.3.8.2. Financial performance 8.3.8.3. Test Type benchmarking 8.3.8.4. Strategic initiatives 8.3.9. Siemens Healthcare GmbH 8.3.9.1. Company overview 8.3.9.2. Financial performance 8.3.9.3. Test Type benchmarking 8.3.9.4. Strategic initiatives 8.3.10. OPKO Health, Inc. 8.3.10.1. Company overview 8.3.10.2. Financial performance 8.3.10.3. Test Type benchmarking 8.3.10.4. Strategic initiatives 8.3.11. Genomic Health. 8.3.11.1. Company overview 8.3.11.2. Financial performance 8.3.11.3. Test Type benchmarking 8.3.11.4. Strategic initiatives 8.3.12. Pfizer Inc. 8.3.12.1. Company overview 8.3.12.2. Financial performance 8.3.12.3. Test Type benchmarking 8.3.12.4. Strategic initiatives
SummaryProstate Cancer Diagnostics Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Segment Definitions 1.2.1. Test Type 1.2.2. Type 1.2.3. End Use 1.2.4. Regional scope 1.2.5. Estimates and forecasts timeline 1.3. Research Methodology 1.4. Information Procurement 1.4.1. Purchased database 1.4.2. GVR’s internal database 1.4.3. Secondary sources 1.4.4. Primary research 1.4.5. Details of primary research 1.4.5.1. Data for primary interviews in North America 1.4.5.2. Data for primary interviews in Europe 1.4.5.3. Data for primary interviews in Asia Pacific 1.4.5.4. Data for primary interviews in Latin America 1.4.5.5. Data for Primary interviews in MEA 1.5. Information or Data Analysis 1.5.1. Data analysis models 1.6. Market Formulation & Validation 1.7. Model Details 1.7.1. Commodity flow analysis (Model 1) 1.7.2. Approach 1: Commodity flow approach 1.7.3. Volume price analysis (Model 2) 1.7.4. Approach 2: Volume price analysis 1.8. List of Secondary Sources 1.9. List of Primary Sources 1.10. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Test Type 2.2.2. Type 2.2.3. End Use 2.2.4. Regional outlook 2.3. Competitive Insights Chapter 3. Prostate Cancer Diagnostics Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Market Dynamics 3.2.1. Market driver analysis 3.2.1.1. Increasing prevalence of prostate cancer 3.2.1.2. Increasing global geriatric population 3.2.1.3. Technological advancements in the field of cancer diagnostics 3.2.2. Market restraint analysis 3.2.2.1. High cost of diagnostics 3.3. Prostate Cancer Diagnostics Market Analysis Tools 3.3.1. Industry Analysis - Porter’s 3.3.1.1. Supplier power 3.3.1.2. Buyer power 3.3.1.3. Substitution threat 3.3.1.4. Threat of new entrant 3.3.1.5. Competitive rivalry 3.3.2. PESTEL Analysis 3.3.2.1. Political landscape 3.3.2.2. Technological landscape 3.3.2.3. Economic landscape Chapter 4. Prostate Cancer Diagnostics Market: Test Type Estimates & Trend Analysis 4.1. Test Type Market Share, 2023 & 2030 4.2. Segment Dashboard 4.3. Global Prostate Cancer Diagnostics Market by Test Type Outlook 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 4.4.1. Preliminary Tests 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.1.2. PSA Tests 4.4.1.2.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.1.3. Free PSA Test 4.4.1.3.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.1.4. Total PSA Test 4.4.1.4.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.1.5. Other Preliminary Tests 4.4.1.5.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2. Confirmatory Tests 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2.2. Pca3 Test 4.4.2.2.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2.3. Trans-Rectal Ultrasound 4.4.2.3.1 Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2.4. Biopsy Test 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 5. Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis 5.1. Type Market Share, 2023 & 2030 5.2. Segment Dashboard 5.3. Global Prostate Cancer Diagnostics Market by Type Outlook 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 5.4.1. Adenocarcinoma 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million) 5.4.2. Interstitial Cell Carcinoma 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) 5.4.3. Other 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 6. Prostate Cancer Diagnostics Market: End Use Estimates & Trend Analysis 6.1. End-use Market Share, 2023 & 2030 6.2. Segment Dashboard 6.3. Global Prostate Cancer Diagnostics Market by End Use Outlook 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 6.4.1. Hospitals 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.2. Outpatient Facilities 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.3. Home Care 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.4. Research & Manufacturing 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 7. Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis 7.1. Regional Market Share Analysis, 2023 & 2030 7.2. Regional Market Dashboard 7.3. Global Regional Market Snapshot 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030: 7.5. North America 7.5.1. U.S. 7.5.1.1. Key country dynamics 7.5.1.2. Regulatory framework/ reimbursement structure 7.5.1.3. Competitive scenario 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) 7.5.2. Canada 7.5.2.1. Key country dynamics 7.5.2.2. Regulatory framework/ reimbursement structure 7.5.2.3. Competitive scenario 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) 7.6. Europe 7.6.1. UK 7.6.1.1. Key country dynamics 7.6.1.2. Regulatory framework/ reimbursement structure 7.6.1.3. Competitive scenario 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) 7.6.2. Germany 7.6.2.1. Key country dynamics 7.6.2.2. Regulatory framework/ reimbursement structure 7.6.2.3. Competitive scenario 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) 7.6.3. France 7.6.3.1. Key country dynamics 7.6.3.2. Regulatory framework/ reimbursement structure 7.6.3.3. Competitive scenario 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) 7.6.4. Italy 7.6.4.1. Key country dynamics 7.6.4.2. Regulatory framework/ reimbursement structure 7.6.4.3. Competitive scenario 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) 7.6.5. Spain 7.6.5.1. Key country dynamics 7.6.5.2. Regulatory framework/ reimbursement structure 7.6.5.3. Competitive scenario 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) 7.6.6. Norway 7.6.6.1. Key country dynamics 7.6.6.2. Regulatory framework/ reimbursement structure 7.6.6.3. Competitive scenario 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) 7.6.7. Sweden 7.6.7.1. Key country dynamics 7.6.7.2. Regulatory framework/ reimbursement structure 7.6.7.3. Competitive scenario 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) 7.6.8. Denmark 7.6.8.1. Key country dynamics 7.6.8.2. Regulatory framework/ reimbursement structure 7.6.8.3. Competitive scenario 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) 7.7. Asia Pacific 7.7.1. Japan 7.7.1.1. Key country dynamics 7.7.1.2. Regulatory framework/ reimbursement structure 7.7.1.3. Competitive scenario 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) 7.7.2. China 7.7.2.1. Key country dynamics 7.7.2.2. Regulatory framework/ reimbursement structure 7.7.2.3. Competitive scenario 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) 7.7.3. India 7.7.3.1. Key country dynamics 7.7.3.2. Regulatory framework/ reimbursement structure 7.7.3.3. Competitive scenario 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) 7.7.4. Australia 7.7.4.1. Key country dynamics 7.7.4.2. Regulatory framework/ reimbursement structure 7.7.4.3. Competitive scenario 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) 7.7.5. South Korea 7.7.5.1. Key country dynamics 7.7.5.2. Regulatory framework/ reimbursement structure 7.7.5.3. Competitive scenario 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) 7.7.6. Thailand 7.7.6.1. Key country dynamics 7.7.6.2. Regulatory framework/ reimbursement structure 7.7.6.3. Competitive scenario 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) 7.8. Latin America 7.8.1. Brazil 7.8.1.1. Key country dynamics 7.8.1.2. Regulatory framework/ reimbursement structure 7.8.1.3. Competitive scenario 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) 7.8.2. Mexico 7.8.2.1. Key country dynamics 7.8.2.2. Regulatory framework/ reimbursement structure 7.8.2.3. Competitive scenario 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) 7.8.3. Argentina 7.8.3.1. Key country dynamics 7.8.3.2. Regulatory framework/ reimbursement structure 7.8.3.3. Competitive scenario 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) 7.9. MEA 7.9.1. South Africa 7.9.1.1. Key country dynamics 7.9.1.2. Regulatory framework/ reimbursement structure 7.9.1.3. Competitive scenario 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) 7.9.2. Saudi Arabia 7.9.2.1. Key country dynamics 7.9.2.2. Regulatory framework/ reimbursement structure 7.9.2.3. Competitive scenario 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) 7.9.3. UAE 7.9.3.1. Key country dynamics 7.9.3.2. Regulatory framework/ reimbursement structure 7.9.3.3. Competitive scenario 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) 7.9.4. Kuwait 7.9.4.1. Key country dynamics 7.9.4.2. Regulatory framework/ reimbursement structure 7.9.4.3. Competitive scenario 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Recent Developments & Impact Analysis, By Key Market Participants 8.2. Company/Competition Categorization 8.3. Vendor Landscape 8.3.1. List of key distributors and channel partners 8.3.2. Key customers 8.3.3. Key company market share analysis, 2023 8.3.4. MDx Health 8.3.4.1. Company overview 8.3.4.2. Financial performance 8.3.4.3. Test Type benchmarking 8.3.4.4. Strategic initiatives 8.3.5. Myriad Genetics, Inc. 8.3.5.1. Company overview 8.3.5.2. Financial performance 8.3.5.3. Test Type benchmarking 8.3.5.4. Strategic initiatives 8.3.6. Abbott Laboratories 8.3.6.1. Company overview 8.3.6.2. Financial performance 8.3.6.3. Test Type benchmarking 8.3.6.4. Strategic initiatives 8.3.7. F. Hoffman-La Roche AG 8.3.7.1. Company overview 8.3.7.2. Financial performance 8.3.7.3. Test Type benchmarking 8.3.7.4. Strategic initiatives 8.3.8. Bayer AG 8.3.8.1. Company overview 8.3.8.2. Financial performance 8.3.8.3. Test Type benchmarking 8.3.8.4. Strategic initiatives 8.3.9. Siemens Healthcare GmbH 8.3.9.1. Company overview 8.3.9.2. Financial performance 8.3.9.3. Test Type benchmarking 8.3.9.4. Strategic initiatives 8.3.10. OPKO Health, Inc. 8.3.10.1. Company overview 8.3.10.2. Financial performance 8.3.10.3. Test Type benchmarking 8.3.10.4. Strategic initiatives 8.3.11. Genomic Health. 8.3.11.1. Company overview 8.3.11.2. Financial performance 8.3.11.3. Test Type benchmarking 8.3.11.4. Strategic initiatives 8.3.12. Pfizer Inc. 8.3.12.1. Company overview 8.3.12.2. Financial performance 8.3.12.3. Test Type benchmarking 8.3.12.4. Strategic initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(診断薬)の最新刊レポート
Grand View Research 社の最新刊レポート
本レポートと同じKEY WORD(cancer)の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/05 10:26 153.43 円 167.28 円 201.52 円 |